^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MSI (Microsatellite instability)

    i
    Other names: MSI | Microsatellite instability
    1d
    Neo-POLEM: A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, University of Southampton | Not yet recruiting --> Recruiting
    Enrollment open • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    IMU-201
    2d
    BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study. (2024-520128-27-00)
    P1/2, N=162, Recruiting, Association Gercor | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation • BRAF wild-type • RAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    5d
    Multi-omics analysis reveals features improving outcomes and immunotherapy resistance in MSS colorectal cancer. (PubMed, iScience)
    Mechanistically, CADM1 was identified as a key molecule associated with MLDMPIS. Functional analyses revealed that CADM1 promotes tumor stemness, thereby enhancing proliferation, invasion, and metastasis in MSS CRC.
    Journal • MSi-H Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    5d
    AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors (clinicaltrials.gov)
    P1, N=464, Recruiting, Amgen | Not yet recruiting --> Recruiting | Trial completion date: Apr 2032 --> Jun 2028 | Trial primary completion date: Apr 2029 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    6d
    Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Mayo Clinic | Trial completion date: Nov 2026 --> Jul 2027 | Trial primary completion date: Jan 2026 --> May 2025
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Odomzo (sonidegib)
    7d
    Immunotherapy of endometrial cancer: a review of recent advances. (PubMed, Immunotherapy)
    While ICIs have demonstrated robust and durable efficacy in dMMR/MSI-H EC, the magnitude of benefit in pMMR disease remains modest. Additionally, we examine promising future directions, including personalized immunotherapy approaches and novel combination therapies (e.g. antibody-drug conjugates, PARP inhibitors, antiangiogenic drugs).
    Review • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    7d
    Integrated Machine Learning and Multi-Omics Identifies a Novel Molecular Signature for Improving the Prognosis of Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    Our research developed an IDMS that could serve as an effective tool for patient stratification management and prognosis prediction. This signature could provide a reference for immunotherapy for patients with HCC and improve their prognosis.
    Journal • IO biomarker
    |
    MSI (Microsatellite instability)
    7d
    Comprehensive Analysis of the Predictive Value of Adenylate Cyclase 4 on Clinical Significance, Prognosis, and Immunotherapy in Human Cancers. (PubMed, Reprod Sci)
    Our collective findings suggest that ADCY4 holds promise as a potential prognostic biomarker and a novel target for cancer immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    7d
    Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=33 --> 44
    Enrollment change • MSI-H
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    7d
    MA-CRC-II-018: Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=48, Recruiting, Hong Qiu
    New P2 trial
    |
    MSI (Microsatellite instability)
    |
    retlirafusp alfa (SHR-1701)
    8d
    Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting
    Enrollment closed • Mismatch repair • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    8d
    Pathway Mutation Accumulate Perturbation Score: A prognostic and predictive biomarker for immunotherapy in advanced gastric cancer. (PubMed, Adv Clin Exp Med)
    The PMAPscore-based risk model is a robust tool for predicting survival and immunotherapy responses in patients with advanced GC, supporting its clinical application for treatment stratification.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    PD-L1 expression